Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEAP-001: Pembrolizumab + Lenvatinib vs Chemotherapy in Advanced/Recurrent Endometrial Carcinoma (First-line)
jRCT2080224638Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab and lenvatinib in endometrial cancer (EC) (2 arms), sponsored by Merck & Co. Primary endpoints: Progression-free survival and Overall survival. Started Apr 2019; status: completed.
02
Drugs
pembrolizumablenvatinib
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on jRCT2080224638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224638.